Oxford BioMedica PLC
Medawar Centre<br>Robert Robinson Avenue
The Oxford Science Park
142 articles with Oxford BioMedica PLC
Papyrus Therapeutics, Inc. (“Papyrus” or the “Company”), an emerging biopharma company developing novel extracellular tumor suppressor therapies for the treatment of cancer and Oxford Biomedica plc (LSE:OXB or the “Group”), a leading gene and cell therapy group, announced today the signing of a research collaboration agreement. The collaboration includes the assessment of the impact and therapeutic benefit of Papyr
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD
Axovant Gene Therapies Ltd, a clinical-stage company developing innovative gene therapies for neurological diseases, announced that its subsidiary has signed a three-year Clinical Supply Agreement with Oxford Biomedica plc, a leading gene and cell therapy group.
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a one year Clinical & Commercial Supply Agreement with AstraZeneca UK Ltd (“AstraZeneca”).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disease
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an R&D collaboration and Option & Licence Agreement to research and develop gene therapy products for the treatment of an inherited retinal disease
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in OXB (the “Subscription Shares”) at a price of £6.90 per share (the “Subscription Price”),
Oxford Biomedica plc (LSE:OXB) (“OXB” or “the Group”), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdings”), has agreed to invest up to £53.5 million in the Group in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase (the “Transaction”).
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
Oxford Biomedica notes that Axovant has announced the dosing of the first patient in the second cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients.
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between 29 April and 2 May in Washington, DC, USA.
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
Approved for the treatment of two distinct indications – CD19-positive relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and CD19-positive r/r diffuse large B-cell lymphoma (DLBCL).
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
The goal is to improve the yield and quality of next-generation gene therapy vectors—typically viruses—using artificial intelligence (AI) and machine learning.
Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning
Cell and gene therapy has the potential to transform medicine, providing long-term and potentially curative treatment options for a wide range of diseases.
Oxford Biomedica notes Axovant's update on Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease
Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease.
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.
Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease
~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below)
The deal includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.